Date: December 7, 2010
Number: OH-P-2010-31
MI-P-2010-20

To: All Providers

From: CareSource

Subject: FDA Withdraws Propoxyphene (Darvocet®) from the Market

This network notification is intended to notify all providers that the United States Food and Drug Administration (FDA) requested that propoxyphene be withdrawn from the U.S. market.

The FDA took this action after receiving new clinical data showing that the drug puts patients at risk of potentially serious or even fatal heart abnormalities.

Drug Labels Affected in the Class II Recall:

- PROPOXYPHENE HCL W/APAP TAB 65-650MG
- DARVOCET-N® TAB 50
- DARVOCET-N® TAB 100
- DARVOCET-N® TAB A500
- DARVON CAP® 65MG
- DARVON-N TAB® 100MG

The FDA recommends that health care providers stop prescribing and dispensing propoxyphene-containing products to patients and inform patients of the risks associated with propoxyphene.

Alternative Pain Management Strategies:

- TRAMADOL
- HYDROCODONE/APAP
- CODEINE/APAP